FDA Drug Recalls

Recalls / Class II

Class IID-0268-2024

Product

Mesalamine Delayed-Release Tablets, USP 1.2 g per tablet, Rx Only, 120 Tablets per bottle, Once Daily, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512, Manufactured by: Sun Pharmaceutical Industries Limited Survey No. 259/15, Dadra-396 191 (U.T. of D & NH), INDIA, NDC 63304-175-13.

Brand name
Mesalamine
Generic name
Mesalamine
Active ingredient
Mesalamine
Route
Oral
NDC
63304-175
FDA application
ANDA211858
Affected lot / code info
Lot #s: DNE0875A Exp. 01/31/2025; DNE0876A, DNE0877A, DNE1080A, DNE1081A Exp. 02/28/2025; DNE1147A, DNE1148A Exp. 03/31/2025.

Why it was recalled

CGMP Deviations: Microbial contamination was reported in stagnant water in the duct of the manufacturing equipment.

Recalling firm

Firm
SUN PHARMACEUTICAL INDUSTRIES INC
Manufacturer
Sun Pharmaceutical Industries, Inc.
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
2 Independence Way, N/A, Princeton, New Jersey 08540-6620

Distribution

Quantity
10,690 bottles
Distribution pattern
Nationwide in the USA

Timeline

Recall initiated
2024-01-18
FDA classified
2024-01-25
Posted by FDA
2024-01-31
Status
Completed

Source: openFDA Drug Enforcement endpoint. Recall record D-0268-2024. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.

Class II recall: Mesalamine · FDA Drug Recalls